Stifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) on May 10 and set a price target of $60.00. The company’s shares closed last Friday at $51.17.

According to TipRanks, Burnett is an analyst with an average return of -10.1% and a 33.33% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Disc Medicine, eFFECTOR Therapeutics, and Iovance Biotherapeutics.

In addition to Stifel Nicolaus, Crispr Therapeutics AG also received a Hold from Barclays’s Gena Wang in a report issued on May 9. However, on May 10, Oppenheimer maintained a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).

CRSP market cap is currently $4.35B and has a P/E ratio of -18.80.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CRSP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Crispr Therapeutics AG (CRSP) Company Description:

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.